| Identification | More | [Name]
PD 0332991 HCl | [CAS]
827022-32-2 | [Synonyms]
PD 0332991 HCl
Palbociclib HCl
PD-0332991 (Palbociclib)
PD 0332991 hydrochloride
Palbociclib (hydrochloride)
Palbociclib (PD-0332991) HCl
6-acetyl-8-cyclopentyl-5-Methyl-2-(5-(piperazin-1-yl)pyridin-2-ylaMino)pyrido[2,3-d]pyriMidin-7(8H)-one hydrochloride
6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one hydrochloride Palbociclib (PD-0332991) HCl | [EINECS(EC#)]
1592732-453-0 | [Molecular Formula]
C24H30ClN7O2 | [MDL Number]
MFCD22420809 | [MOL File]
827022-32-2.mol | [Molecular Weight]
483.994 |
| Chemical Properties | Back Directory | [storage temp. ]
= -70C | [solubility ]
≥14.48 mg/mL in H2O; ≥2.42 mg/mL in DMSO; ≥2.79 mg/mL in EtOH with gentle warming and ultrasonic | [form ]
Yellow liquid | [color ]
Light yellow to yellow | [Water Solubility ]
water: 10mg/mL | [InChIKey]
STEQOHNDWONVIF-UHFFFAOYSA-N | [SMILES]
O=C1C(=C(C)C2=CN=C(NC3N=CC(N4CCNCC4)=CC=3)N=C2N1C1CCCC1)C(=O)C.Cl |
| Hazard Information | Back Directory | [Description]
PD 0332991 is an orally active, selective inhibitor of the cyclin D kinases Cdk4 (IC50 = 11 nM) and Cdk6 (IC50= 16 nM) with no activity against a panel of 36 additional protein kinases.1 It has been reported to have antiproliferative activity against retinoblastoma-positive tumor cells, blocking retinoblastoma phosphorylation and inducing G1 arrest at nanomolar concentrations.1 PD 0332991 can inhibit the growth of certain ER-positive or HER2-amplified breast cancer cells (IC50s as low as 4 nM) and demonstrates synergy with tamoxifen (Item No. 13258) and trastuzumab, respectively.2 PD 0332991 inhibition of Cdk4 activity has been used to demonstrate a role for insulin-activated cyclinD1-Cdk4 signaling in the control of glucose metabolism that is independent of cell cycle progression.3 | [Uses]
PD 0332991 is an orally active, selective CDK4/6 inhibitor that blocks pRb phosphorylation at serine 780 and 795 in the low nanomolar range and is in clinical development for the treatment of solid tumors[3][4]. | [General Description]
A cell-permeable, orally available and brain permeant, non-toxic pyridopyrimidinone compound that acts as a potent, selective, reversible, ATP competitive inhibitor of Cdk4 and Cdk6 (IC50 = 11, 9, and 15 nM for Cdk4/D1, Cdk4/D3 and Cdk6/D2, respectively). Hence, it reduces retinoblastoma protein phosphorylation at Ser780/Ser795 (IC50 = 66 nM in MDA-435 cells) and arrests cell cycle at G1 phase. Acts as a cytostatic agent, but does induce apoptotic cell death when used alone. However, it potentiates the cytotoxicity of dexamethasone (>Cat. No. 265005), bortezomib (>Cat. No. 504314), and tamoxifen (Cat. No. 579000) in estrogen receptor (ER)-positive cell lines. Exhibits only a trivial inhibitory activity towards Cdk2/E2, Cdk2/A, Cdk1/B and Cdk5/p25 in a 36-kinase panel (IC50 >10 μM). Improves endoderm differentiation of late G1-human embryonic stem cells expressing Smad2 or Smad3 (~ 750 nM) and further enhances endoderm differentiation into hepatic and pancreatic progenitor cells. Shown to regress the growth of human breast tumor xenografts in murine models (~150 mg/kg, p.o., daily). | [Biochem/physiol Actions]
Cell permeable: yes | [Synthesis]
Synthesis of 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one hydrochloride from tert-butyl 4-[6-[[8-cyclopentyl-6-(1-ethoxyethenyl)-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl]amino]pyridin-3-yl]piperazin-1-carboxylate. [2,3-d]pyrimidin-7(8H)-one hydrochloride was prepared in the following general procedure: to tert-butyl 4-[6-[[8-cyclopentyl-6-(1-ethoxyvinyl)-5-methyl-7-oxo-7,8-dihydropyrido[2,3-D]pyrimidin-2-yl]amino]pyridin-3-yl]piperazine-1-carboxylate under ice-bath cooling conditions (4.50 g. 0.00783 mol, as prepared in Example 2) in a solution of dichloromethane (100 mL) was bubbled with hydrogen chloride gas. The resulting suspension was sealed and stirred overnight at room temperature and subsequently diluted with ether (200 mL). The solid was collected by filtration, washed with ether and dried to afford 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one hydrochloride as a yellow solid (4.01 g, 92% yield). | [target]
CDK4/cyclin D1 | [storage]
Store at -20°C | [References]
[1] ivan diaz-padilla, lillian l. siu and ignacio duran. cyclin-dependent kinase inhibitors as potential targeted anticancer agents. invest new drugs. 2009, 27: 586–594.
[2] richard s finn, judy dering, dylan conklin, ondrej kalous, david j cohen, amrita j desai, charles ginther, mohammad atefi, isan chen, camilla fowst, gerret los and dennis j slamon. pd 0332991, a selective cyclin d kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. breast cancer research. 2009, 11: r77. |
|
| Company Name: |
Energy Chemical
|
| Telephone: |
400-0056266 |
| Website: |
www.energy-chemical.com |
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Telephone: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15748/0_EN.htm |
|